Audio conference highlights
A 60-million Euro fine for AstraZeneca. A 10-million Euro fine for Bayer. Dawn raids at Pfizer, SanofiAventis and GlaxoSmithKline. Pharma and medical device companies have been targeted in a number of major antitrust investigations in Europe in recent years. It is absolutely vital that any company doing business in Europe be aware of existing antitrust provisions, and perhaps especially important for those in the life sciences. This presentation gives a general overview of EU antitrust law, and highlights those areas of particular relevance to medical device and pharmaceutical companies. The presentation places added emphasis on identifying special areas of risk, such as agreements restricting competition, information sharing between competitors, distribution agreements and abuse of market-dominating positions. Our speakers also discuss when you should seek legal assistance, and how to behave in the event of dawn raids.
This audio conference covers:
- An overview of EU antitrust law
- Risks of infringements of EU antitrust law
- Behavior in case of dawn raids
- When to seek legal advice
- Compliance tools
About the speakers:
Marc Besen is a Partner and Dr. Christian Mayer is an Associate at the Düsseldorf office of the law firm of Clifford Chance. They are members of the global Healthcare. Life Sciences & Chemicals Industry Group. They specialize in European competition law, particularly in connection with cartel investigations, proceedings on abuse of market-dominating positions, corporate acquisitions, joint ventures, and distribution and licensing agreements with a broad industry focus. This includes the medical device, pharmaceutical, biotechnology, food and chemical industries.
Who should attend?
- Legal counsel
- Senior management
- Marketing
- Business development
- Intellectual property department
- All employees who contact competitors and/or customers
*Please note: Each registration covers one line connected to the audio conference. Attendees dialing from separate locations are required to have separate registrations.